Skip to main content
. 2020 Dec 28;22(1):210. doi: 10.3390/ijms22010210

Figure 2.

Figure 2

Effects of growth hormone secretagogoue receptors (GHS-R1A) antagonist (JMV2959) on WIN55,212-2-induced dopamine and its metabolites’ extracellular changes in the rat nucleus accumbens shell (NACSh). JMV2959 3 mg/kg was given i.p. 20 min before 2.4 mM/0.5 µL WIN55,212-2 or vehicle 0.5 µL was administered into the posterior ventral tegmental area (VTA) injection (n = 6; means ± SEM). Changes in accumbens dopamine are illustrated in graph (A), changes in homovanillic acid (HVA), 3-methoxytyramine (3-MT) and 3,4-dihydroxyphenylacetic acid (DOPAC) are illustrated in the graphs (B–D), respectively. The effects are illustrated as follows: saline + WIN55,212-2 (filled circle; n = 7), 3 mg/kg JMV2959 + WIN55,212-2 (open circle; n = 6), 3 mg/kg JMV2959 + vehicle (open triangle; n = 4), saline + vehicle (dotting; n = 7). Differences between saline + WIN55,212-2 and saline + vehicle groups are expressed as *** p < 0.001, * p < 0.05. Differences JMV2959 + WIN55,212-2 and saline + vehicle groups are expressed as +++ p < 0.001, ++ p < 0.01, + p < 0.05. Differences between groups saline + WIN55,212-2 and 3 mg/kg JMV2959 + WIN55,212-2 are expressed as ### p < 0.001, # p < 0.05.